Pharmacologic treatment of tardive dyskinesia: A meta-analysis and systematic review

Abstract

Objective: To examine the efficacy of pharmacologic treatments for tardive dyskinesia (TD). Data Sources: PubMed was searched on December 12, 2017, for randomized, placebo-controlled trials examining the treatment of TD using the search terms (drug-induced dyskinesia OR tardive dyskinesia) AND (psychotic disorders OR schizophrenia). Study Selection: Studies were included if they examined tardive dyskinesia treatment as the primary outcome and were randomized and placebo-controlled trials. Data Extraction: The effect size (standard mean difference) of improvement (compared to placebo) stratified by medication class is reported for each of the trials included in this systematic review. A meta-analysis was conducted utilizing a fixed-effects model. Results: Vitamin E was associated with significantly greater reduction in TD symptoms compared to placebo (standardized mean difference [SMD] = 0.31 ± 0.08; 95% CI, 0.16 to 0.46; z= 4.1; P